International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Pilaralisib (Primary) ; Voxtalisib (Primary) ; Bendamustine; Carboplatin; Letrozole; Paclitaxel; Temozolomide; Trastuzumab
- Indications Cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 25 Sep 2018 Planned End Date changed from 6 Jun 2018 to 23 May 2018.
- 25 Sep 2018 Planned primary completion date changed from 6 Jun 2018 to 23 May 2018.
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.